Publications by authors named "D Toppmeyer"
Purpose: The Genetic Risk Assessment for Cancer Education and Empowerment Project demonstrated that tailored counseling and navigation (TCN) substantially increased the rate of genetic evaluation (GE) in women with high-risk breast or ovarian cancer (odds ratio, 8.9 [95% CI, 3.4 to 23.
View Article and Find Full Text PDFFirst Results of the Primary Outcome of a Phase 2 Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Patients With Breast Cancer.
Int J Radiat Oncol Biol Phys
February 2025
Purpose: A radiation therapy (RT) boost to the tumor bed is an important component of breast-conserving therapy in early breast cancer. This prospective phase 2 study assessed the feasibility of delivering the RT boost before surgery. We hypothesize wound complication rates to be comparable with postoperative RT and the target boost volume to be smaller than standard postoperative RT.
View Article and Find Full Text PDFPurpose: Cancer genetic risk assessment (CGRA) is recommended for women with ovarian and high-risk breast cancer. However, the underutilization of CGRA has long been documented, and cost has been a major barrier. In this randomized controlled trial, a tailored counseling and navigation (TCN) intervention significantly improved CGRA uptake at 6-month follow-up, compared with targeted print (TP) and usual care (UC).
View Article and Find Full Text PDFPurpose Of Review: Pre-menopausal women diagnosed with hormone receptor (HR) breast cancer are candidates for prolonged hypoestrogenism to improve cancer outcomes. However, the disease benefit eclipses the toxicities associated with ovarian function suppression (OFS), which are often under-reported.
Recent Findings: Increased risk of mortality from cardiovascular disease, bone disorders, and metabolic disorders is well reported in women with no history of cancer, after surgical oophorectomy or premature ovarian failure.
Article Synopsis
- The study investigates the long-term outcomes of accelerated partial breast irradiation (APBI) in early-stage breast cancer patients, focusing on daily doses that are equivalent to whole breast radiation.
- Over a 12-year follow-up, a total of 34 patients were treated, with a low recurrence rate of 5.8% and high survival rates of 93.5% for breast recurrence-free and 93.2% overall.
- The findings suggest that this APBI method is well-tolerated, with most patients achieving good to excellent cosmetic results while experiencing minimal long-term side effects.